News summaryYahoo Finance / BenzingaNov 7, 2026, 06:13 AM
Iovance Biotherapeutics (IOVA) Q3 Earnings Sharpen Focus On Margin Recovery - Yahoo Finance
Iovance reported Q3 2026 revenue of US$121.5 million, up from US$67.5 million a year earlier. [[fact-aofwmt32a]] Its Q3 net loss was US$22.3 million, compared with US$91.3 million a year earlier. [[fact-908q1had6]] Gross margin rose to roughly 60% in Q3 2026 from roughly 56% in Q2 2026. [[fact-eadqqod7d]] The company reiterated 2026 revenue guidance of US$410 million to US$420 million. [[fact-nor463l2t]]